Evolving evidence of diabetic ketoacidosis in patients taking sodium glucose cotransporter 2 inhibitors

Type 1 DiabetesDiabetic Complications

Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis

Diabetes Care.

Hampp C, Swain RS, Horgan C, Dee E, Qiang Y, Dutcher SK, Petrone A, Chen Tilney R, Maro JC, Panozzo CA

doi: 10.2337/dc19-1481.

COMMENTED

Diabetes - GeneralType 2 Diabetes

Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes

JAMA Intern Med.

Chang HY, Singh S, Mansour O, Baksh S, Alexander GC

doi: 10.1001/jamainternmed.

COMMENTED

Type 1 Diabetes

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors

Diabetes Care.

Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M

doi: 10.2337/dc18-

Type 2 Diabetes

Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study

Diabetes Obes Metab.

Birkeland KI, Bodegard J, Banerjee A, Kim DJ, Norhammar A, Eriksson JW, Thuresson M, Okami S, Ha KH, Kossack N, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T

doi: 10.1111/dom.14189.

Diabetes - GeneralType 2 Diabetes

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

Lancet Diabetes Endocrinol.

Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A

doi: 10.1016/

COMMENTED

Diabetes - GeneralType 2 DiabetesGlycemic Control

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis

JAMA.

Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K

doi: 10.1001/jama.2018.3024.

Type 2 DiabetesDiabetic Complications

SGLT2 inhibitors and risk of diabetic ketoacidosis in patients with type 2 diabetes: systematic review and meta-analysis of randomized controlled trials

Diabetes Obes Metab.

Liu J, Li L, Li S, Wang Y, Qin X, Deng K, Liu Y, Zou K, Sun X

doi: 10.1111/dom.14075.

COMMENTED

Type 2 Diabetes

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study

BMJ.

Ueda P, Svanström H, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B

doi: 10.1136/bmj.k4365.

Diabetes - GeneralGlycemic Control

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis

J Am Heart Assoc.

Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, Carbone S, Abbate A, Dixon DL

doi: 10.1161/JAHA.117.005686.

Related content

Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis

Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors

Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis

SGLT2 inhibitors and risk of diabetic ketoacidosis in patients with type 2 diabetes: systematic review and meta-analysis of randomized controlled trials

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis